Advertisement

Annals of Surgical Oncology

, Volume 10, Issue 8, pp 927–934 | Cite as

Intra-Arterial Infusion Chemotherapy With Angiotensin-II for Locally Advanced and Nonresectable Pancreatic Adenocarcinoma: Further Evaluation and Prognostic Implications

  • Hiroaki Ohigashi
  • Osamu Ishikawa
  • Shigekazu Yokayama
  • Yo Sasaki
  • Terumasa Yamada
  • Shingi Imaoka
  • Akihiko Nakaizumi
  • Hiroyuki Uehara
Original Articles

Abstract

Background: For locally advanced and nonresectable cancer of the pancreas, we performed intra-arterial infusion chemotherapy with angiotensin-II (AT-II). In our preliminary report, this treatment resulted in a median of 14 months of survival without objective adverse effects. This study was designed to clarify the prognostic factor in this chemotherapy by using a larger number of cases.

Methods: For 32 patients, intra-arterial chemotherapy was performed: 1 or 2 catheters were intraoperatively placed into the pancreas-supplying arteries. The tissue blood flow and its change by AT-II infusion were determined. For intra-arterial chemotherapy, a mixture of methotrexate (50 or 100 mg/m2) and AT-II (.4 μg/kg/hour) was repeatedly infused from the catheter, mainly at our outpatient clinic.

Results: With our intra-arterial chemotherapy, the median survival period was 13 months. The median survival period was 19 months in patients without coexisting pancreatitis but was only 9 months in those with it (P = .0003). The presence or absence of coexisting fibrosis in the neighboring uninvolved pancreas offered the only prognostic indicator. The blood flow in cancerous tissue was increased during AT-II infusion, and this was characteristic in the patients whose neighboring uninvolved pancreas had normal parenchyma (nonatrophic) or higher blood flow before AT-II infusion.

Conclusions: Because the AT-II infusion played a role in shifting the blood flow from the surrounding uninvolved pancreas to the cancer tissues, we can speculate that cancer tissues might have thereby received a higher dose of anticancer drugs if the surrounding uninvolved pancreas had been nonfibrotic and more rich in tissue blood flow.

Key Words

Locally advanced pancreatic cancer Angiotensin-II Hemodynamic change Coexisting pancreatitis Intra-arterial infusion chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Arbuck S. Overview of chemotherapy for pancreatic cancer. Int J Pancreatol 1990;7:209–22.PubMedGoogle Scholar
  2. 2.
    Rothman H, Cantrell JE Jr, Lokich J, et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. Cancer 1991;68:264–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Rougier P, Zarba JJ, Ducreux M, et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4:333–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 1988;295:91–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Oster MW, Gray R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986;57:29–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Ryan DP, Kulke MH, Fuchs CS, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002;94:97–103.CrossRefPubMedGoogle Scholar
  7. 7.
    Nguyen TD, Theobald S, Rougier P, et al. Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. Radiother Oncol 1997;45:129–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Ardalan B, Ucar A, Reddy R, et al. Phase I trial of low dose N-phosphonacetyl-l-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. Cancer 1994;74:1869–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Thomas CR Jr, Weiden PL, Traverso LW, Thompson T. Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). Am J Clin Oncol 1997;20:161–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293–302.CrossRefPubMedGoogle Scholar
  11. 11.
    Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 2002;94:902–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Gazet JC, Smith R. Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas. Proc R Soc Med 1974;67:1182–3.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Hafstroem L, Ihse I, Joensson P, Lunderquist A, Stridbeck H. Intraarterial 5-FU infusion with or without oral testolactone treatment in irresectable pancreatic cancer. Acta Chir Scand 1980;146:445–8.Google Scholar
  14. 14.
    McCracken JD, Olson M, Cruz AB, Leichman L, Oishi N. Radiation therapy combined with intra-arterial 5-FU chemotherapy for treatment of localized adenocarcinoma of the pancreas. Cancer Treat Rep 1982;66:549–51.PubMedGoogle Scholar
  15. 15.
    Smith L, Gazet J. Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas. Ann R Coll Surg Engl 1980;62:208–12.Google Scholar
  16. 16.
    Theodors A, Bukowski R, Hewlett J, Livinfston R, Weick J. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Am J Clin Oncol 1982;5:555–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Ishida H, Makino T, Kobayashi M, Tsuneoka K. Laparoscopic measurement of pancreatic blood flow. Endoscopy 1983;15:107–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Ohigashi H, Ishikawa O, Nakamori S, et al. Evaluation of intra-arterial infusion chemotherapy and radical pancreatectomy for patients with locally advanced pancreatic cancer. Jpn J Cancer Chemother 1993;20:1672–5.Google Scholar
  19. 19.
    Aukland K, Bower BF, Berliner RW. Measurement of local blood flow with hydrogen gas. Circ Res 1964;14:164–87.CrossRefPubMedGoogle Scholar
  20. 20.
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–14.CrossRefPubMedGoogle Scholar
  21. 20A.
    Sobin LH, Wittekind Ch. International Union Against Cancer (UICC), TNM Classification of Malignant Tumors. 6th ed. New York: Wily-Liss, 2002.Google Scholar
  22. 21.
    Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma. Cancer 1981;47:1724–8.CrossRefPubMedGoogle Scholar
  23. 22.
    Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–13.CrossRefGoogle Scholar
  24. 23.
    Ohigashi H, Ishikawa O, Sasaki Y, Imaoka S, Iwanaga T. Pancreas cancer: arterial infusion chemotherapy for advanced pancreatic cancer Taguchi T Eds. Arterial Infusion Chemotherapy: Revised and Updated Edition. Tokyo:: Japanese Journal of Cancer and Chemotherapy Publications Inc, 1994: 416–26.Google Scholar
  25. 24.
    Noguchi S, Miyauchi K, Nishizawa Y, et al. Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma. Cancer 1988;62:467–73.CrossRefPubMedGoogle Scholar
  26. 25.
    Sasaki Y, Imaoka S, Hasegawa Y, et al. Changes in distribution of blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer. Cancer 1985;55:311–6.CrossRefPubMedGoogle Scholar
  27. 26.
    Hemingway D, Angerson WJ, Anderson JH, Goldberg JA, McArdle CS, Cooke TG. Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II. Br J Cancer 1992;66:958–60.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 27.
    Sasaki Y, Imaoka S, Hasegawa Y, et al. Distribution of arterial blood flow in human hepatic cancer during chemotherapy: examination by short-lived 81mKr. Surgery 1985;97:409–14.PubMedGoogle Scholar
  29. 28.
    Homma H, Doi T, Mezawa S, et al. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 2000;89:303–13.CrossRefPubMedGoogle Scholar
  30. 29.
    Urbach DR, Swanstrom LL, Hansen PD. The effect of laparoscopy on survival in pancreatic cancer. Arch Surg 2002;137:191–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • Hiroaki Ohigashi
    • 1
    • 3
  • Osamu Ishikawa
    • 1
  • Shigekazu Yokayama
    • 1
  • Yo Sasaki
    • 1
  • Terumasa Yamada
    • 1
  • Shingi Imaoka
    • 1
  • Akihiko Nakaizumi
    • 2
  • Hiroyuki Uehara
    • 2
  1. 1.Department of SurgeryOsaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  2. 2.Department of Internal MedicineOsaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  3. 3.Department of SurgeryOsaka Medical Center for Cancer and Cardiovascular DiseasesHigashinari-kuJapan

Personalised recommendations